ITM and ANSTO Announce Extension of Licensing Agreement for the Production and Supply of the Medical Radioisotope n.c.a. Lutetium-177

MUNICH & SYDNEY--(BUSINESS WIRE)--ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, and the Australian Nuclear Science and Technology Organisation (ANSTO), a public research organization and international leader in the field of nuclear science and technology, today announced the extension of their partnership by entering into a further long-term licensing agreement. Under the terms of the agreement, ANSTO will continue producing n.c.a. 177Lu for the Australian a